Consensus Inventiva

Stocks

IVA

FR0013233012

Biotechnology & Medical Research

Real-time Euronext Paris 05:00:56 2026-10-08 EDT			5-day change	1st Jan Change
2.890 ^EUR	-3.02%		-5.09%	-26.74%

10-02	Truist Raises Price Target on Inventiva to $18 From $13, Keeps Buy Rating	MT
09-29	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT

Evolution of the Average Target: Inventiva

Evolution of the Target Price: Inventiva

Changes in Analyst Recommendations: Inventiva

1369210a4d0f14f.zm8tq0WuFnX-8939EDWgTqA4JLSC5PiOis83ktA76uM.pQpMxhfaXAW9tp-tT1zyHvYMUfDW14jEwP5N05tC04GAQmXAGvZcHpGmug~f0462287138d9c0d7cd99a6973de0a5f

Analysts' recommendations: Inventiva

10-02	Truist Raises Price Target on Inventiva to $18 From $13, Keeps Buy Rating	MT
07-17	Cantor Fitzgerald Initiates Inventiva SA ADR at Overweight	MT
06-03	KBC Securities maintains Buy rating on Inventiva following restructuring
05-27	Inventiva supported by KBC Securities
03-31	Alstom gains momentum, Inventiva underperforms
03-19	Truist Initiates Inventiva at Buy With $13 Price Target	MT
02-02	Biotech Inventiva's 50% surge shows investor optimism over liver disease drug	RE
01-07	UBS Upgrades Inventiva to Buy From Neutral, Adjusts Price Target to $12 From $3	MT
11-24	KBC Maintains "Buy" Rating on Inventiva, Lowers Target Price
11-13	KBC Welcomes Inventiva's Fundraising Initiative
11-06	Wolfe Research Initiates Coverage on Inventiva SA ADR With Outperform Rating	MT
24-04-08	Canaccord Genuity Adjusts Price Target on Inventiva to $20 From $12, Maintains Buy Rating	MT
24-04-08	Inventiva: Canaccord Genuity raises target
24-02-16	Stifel Cuts Price Target on Inventiva to $25 From $27, Maintains Buy Rating	MT
23-12-21	HC Wainwright Adjusts Price Target on Inventiva to $24 From $36, Keeps Buy Rating	MT
23-10-27	Canaccord Genuity Initiates Inventiva at Buy Rating With $12 Price Target	MT
23-05-31	Roth MKM Starts Inventiva at Buy, $11 Price Target	MT
23-03-31	HC Wainwright Trims Price Target on Inventiva to $35 From $36, Keeps Buy Rating	MT
23-03-17	Stifel Initiates Inventiva at Buy With $27 Price Target	MT
22-09-23	HC Wainwright Adjusts Price Target on Inventiva to $36 From $42, Reiterates Buy Rating	MT
21-11-22	HC Wainwright Adjusts Inventiva's Price Target to $42 from $40, Keeps Buy Rating	MT
21-09-22	Inventiva S A : HC Wainwright Lifts Price Target on Inventiva to $40 From $38, Maintains Buy Rating	MT
21-08-02	Inventiva S A : Chardan Suspends Coverage on Inventiva at Buy Rating With 14 Euro Price Target	MT
21-03-08	Inventiva S A : Societe Generale Downgrades Inventiva to Sell Rating From Buy	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	INVENTIVA					+227.85%
	WUXI APPTEC CO., LTD.					+13.99%
	ARGENX SE					+24.63%
	LONZA GROUP AG					+19.23%
	REVOLUTION MEDICINES, INC.					+28.86%
	IQVIA HOLDINGS INC.					+13.19%
	BEONE MEDICINES AG					+19.55%
	CELLTRION, INC.					+45.91%
	BIONTECH SE					+22.24%
	INSMED INCORPORATED					+94.36%
	Average					+50.98%
	Weighted average by Cap.					+26.56%